| Reactive oxygen species and ischemic cerebrovascular disease I Olmez, H Ozyurt Neurochemistry international 60 (2), 208-212, 2012 | 351 | 2012 |
| Diagnostic and therapeutic aspects of Hashimoto's encephalopathy I Olmez, H Moses, S Sriram, H Kirshner, AH Lagrange, S Pawate Journal of the Neurological Sciences 331 (1-2), 67-71, 2013 | 164 | 2013 |
| Combined CDK4/6 and mTOR inhibition is synergistic against glioblastoma via multiple mechanisms I Olmez, B Brenneman, A Xiao, V Serbulea, M Benamar, Y Zhang, ... Clinical Cancer Research 23 (22), 6958-6968, 2017 | 85 | 2017 |
| Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung … I Olmez, BR Donahue, JS Butler, Y Huang, P Rubin, Y Xu Lung cancer 70 (2), 174-179, 2010 | 73 | 2010 |
| A randomized trial of the effectiveness of the neutropenic diet versus food safety guidelines on infection rate in pediatric oncology patients KM Moody, RA Baker, RO Santizo, I Olmez, JM Spies, A Buthmann, ... Pediatric blood & cancer 65 (1), e26711, 2018 | 70 | 2018 |
| Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha I Olmez, S Love, A Xiao, L Manigat, P Randolph, BD McKenna, BP Neal, ... Neuro-oncology 20 (2), 192-202, 2018 | 63 | 2018 |
| Dedifferentiation of patient‐derived glioblastoma multiforme cell lines results in a cancer stem cell‐like state with mitogen‐independent growth I Olmez, W Shen, H McDonald, B Ozpolat Journal of cellular and molecular medicine 19 (6), 1262-1272, 2015 | 63 | 2015 |
| Combined c-Met/Trk inhibition overcomes resistance to CDK4/6 inhibitors in glioblastoma I Olmez, Y Zhang, L Manigat, M Benamar, B Brenneman, I Nakano, ... Cancer research 78 (15), 4360-4369, 2018 | 57 | 2018 |
| CDK4/6 inhibition is more active against the glioblastoma proneural subtype M Li, A Xiao, D Floyd, I Olmez, J Lee, J Godlewski, A Bronisz, KPL Bhat, ... Oncotarget 8 (33), 55319, 2017 | 46 | 2017 |
| Statins affect human glioblastoma and other cancers through TGF-β inhibition A Xiao, B Brenneman, D Floyd, L Comeau, K Spurio, I Olmez, J Lee, ... Oncotarget 10 (18), 1716, 2019 | 37 | 2019 |
| Drop in platelet counts in extremely preterm neonates and its association with clinical outcomes S Rastogi, I Olmez, A Bhutada, D Rastogi Journal of pediatric hematology/oncology 33 (8), 580-584, 2011 | 26 | 2011 |
| NCI classification of thrombocytopenia in extremely preterm neonates and its association with mortality and morbidity S Rastogi, I Olmez, A Bhutada, D Rastogi Walter de Gruyter 39 (1), 65-69, 2011 | 21 | 2011 |
| Analysis of significant decrease in platelet count and thrombocytopenia, graded according to NCI-CTC, as prognostic risk markers for mortality and morbidity I Olmez, M Zafar, M Shahid, S Amarillo, R Mansfield Journal of pediatric hematology/oncology 33 (8), 585-588, 2011 | 18 | 2011 |
| Adult-onset adrenoleukodystrophy presenting after chemotherapy: No black and white matter D Isaacs, I Olmez, DO Claassen Neurology: Clinical Practice 4 (2), 168-170, 2014 | 2 | 2014 |
| The Ketogenic Diet–Induced Weight Gain With Decreased Energy Consumption I Olmez, M Montgomery, KC James, JE Pina-Garza ICAN: Infant, Child, & Adolescent Nutrition 5 (1), 29-31, 2013 | 1 | 2013 |
| Compositions and methods for treating cancer B Purow, D Floyd, I Olmez, TE Harris, S Boroda US Patent 10,946,020, 2021 | | 2021 |
| CSIG-32. ACTIVATED Trk/Met PATHWAY IS A NOVEL RESISTANCE MECHANISM FOR CDK4/6 INHIBITORS THAT CAN BE TARGETED WITH A SPECIFIC SMALL MOLECULE INHIBITOR I Olmez, B Purow Neuro-Oncology 19 (Suppl 6), vi56, 2017 | | 2017 |
| TARGETING MESENCHYMAL GLIOBLASTOMA THROUGH INHIBITION OF DIACYLGLYCEROL KINASE ALPHA I Olmez, S Love, D Floyd, M Li, T Harris, B Purow NEURO-ONCOLOGY 18, 48-48, 2016 | | 2016 |
| Unusual Toxicities and Clinical Outcomes in Extracranial Tumor Sites With Concurrent Whole-Brain Radiation Therapy and Erlotinib Treatment in Patients With Non–Small-Cell Lung … I Olmez, YJ Huang, BR Donahue, JS Butler, P Rubin, Y Xu Clinical Lung Cancer 5 (10), E18, 2009 | | 2009 |
